Back to mobile site

BioDelivery Sciences (BDSI) Secures U.S. Commercial Partnership for BEMA Fentanyl with Meda AB

September 5, 2007 9:43 AM EDT Send to a Friend
BioDelivery Sciences International, Inc. (Nasdaq: BDSI) has entered into an exclusive and perpetual license and related supply agreement with Meda ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login